Based in Boston, Elucid leverages machine learning to improve the accuracy, experience, and cost-effectiveness of cardiovascular diagnostic imaging. Their flagship product, ElucidVivo, is the first FDA-cleared software for evaluating plaque vulnerability from a single CTA to inform risk of event and treatment selection. Elucid also provides quantitative image analysis services to pharmaceutical companies, providers, and research organizations. Their uniquely interpretable and validated AI provides physicians with critical information to optimize treatment decisions for patients with cardiovascular disease. Elucid is the first FDA-cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company's studies have also shown improved treatment decisions by physicians, leading to better patient outcomes, improved quality of care, and reduced healthcare costs.